<DOC>
	<DOCNO>NCT02891720</DOCNO>
	<brief_summary>The goal study evaluate integrate technology system confirm ingestion oral PrEP , monitor adherence real-time longitudinally , provide visual feedback mechanism promote enhanced adherence behavior .</brief_summary>
	<brief_title>Feasibility Ingestible Sensor System Measure PrEP Adherence YMSM</brief_title>
	<detailed_description>In order evaluate feasibility acceptability PSS FTC/TDF PrEP , 100 HIV-negative YMSM randomize Advances Technology Enhance Adherence Monitoring ( A-TEAM ) pilot study 12 week daily FTC/TDF PSS versus daily FTC/TDF standard-of-care ( SOC ) , arm crossover 12 week daily FTC/TDF without sensor system versus sensor system , respectively . PrEP provide study ( see Gilead letter ) aspects PrEP clinical care consistent PrEP Clinic 's standard practice base CDC clinical guideline . The detection accuracy PSS correlate DBS-determined TFV-DP FTC-TP level obtain monthly participant . A relationship TVF-DP DBS adherence FTC/TDF PrEP precede 1-3 month previously characterize . These adherence category implement iPrEx OLE consist : low limit quantitation ( BLQ ) , &gt; BLQ 349 fmol per punch ( few two tablet per week ) , 350-699 fmol per punch ( two three tablet per week ) , 700-1249 fmol per punch ( four six tablet per week ) , 1250 fmol per punch ( daily dosing ) . Real-time visual feedback medication ingestion provide participant via PSS transmit study team . A weekly text message estimate HIV risk reduction base upon DBS algorithm transmit participant initial first week FTC/TDF dosing . Finally , in-depth qualitative exploration barrier facilitator use PSS component complete individual interview well focus group discussion participant . Participants also provide feedback text message regard PrEP protection well suggestion potential method receive performance data .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Young men meet follow criterion eligible inclusion : PrEPeligible YMSM Ages 1824 Biologically bear male Report interest PrEP Intend use PrEP full 6 month period Eligible PrEP patient CORE Center PrEP Clinic Meet one follow sexual risk criterion : Have HIVpositive sexual partner Had recent bacterial STI Report high number sexual partner Report history inconsistent condom use Report exchange/transactional sex . Exclusion Criteria Young men meet follow criterion exclude : HIV+ Creatinine clearance &lt; 60 cc/min ) Allergy topical adhesive Acute gastrointestinal symptom History major GI surgery Presence implant electronic medical device . Subjects receive follow medication : Nephrotoxic drug ( e.g. , cidofovir , amphotericin , aminoglycosides , dapsone , tacrolimus , foscarnet , ACE inhibitor ) , diuretic , drug may interfere TFV excretion ( e.g. , ( Val ) ganciclovir , Cyclosporin A , Sirolimus , Antineoplastics ) , drug ( include mineral vitamin supplement ) use treatment osteoporosis ( e.g. , alendronate bisphosphonates , teriparatide , denosumab , calcitonin ) , chronic use oral systemic steroid ( i.e. , daily use two week allow ) , experimental medication Food Drug Administration ( FDA ) approve , FTC/TDF ( TruvadaÂ® ) receive outside study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>